These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15812534)

  • 1. Novel approaches in GVHD therapy.
    Svennilson J
    Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S65-7. PubMed ID: 15812534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
    Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
    Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the management of acute graft-versus-host disease.
    Bolaños-Meade J
    Curr Opin Oncol; 2006 Mar; 18(2):120-5. PubMed ID: 16462179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mesenchymal stem cells as salvage therapy for steroid resistant acute graft-versus-host disease following haploidentical hematopoietic stem cell transplantation].
    Xue M; Wang ZD; Dong L
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):878-80. PubMed ID: 22339970
    [No Abstract]   [Full Text] [Related]  

  • 6. Graft-versus-host disease: emerging concepts in prevention and therapy.
    Dean RM; Bishop MR
    Curr Hematol Rep; 2003 Jul; 2(4):287-94. PubMed ID: 12901325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy by allogeneic stem cell transplantation.
    Ringdén O
    Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of acute graft-versus-host disease.
    Bacigalupo A
    Br J Haematol; 2007 Apr; 137(2):87-98. PubMed ID: 17391488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.
    Ringdén O; Uzunel M; Rasmusson I; Remberger M; Sundberg B; Lönnies H; Marschall HU; Dlugosz A; Szakos A; Hassan Z; Omazic B; Aschan J; Barkholt L; Le Blanc K
    Transplantation; 2006 May; 81(10):1390-7. PubMed ID: 16732175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells.
    Fang B; Song YP; Liao LM; Han Q; Zhao RC
    Bone Marrow Transplant; 2006 Sep; 38(5):389-90. PubMed ID: 16878145
    [No Abstract]   [Full Text] [Related]  

  • 11. Two cases of cutaneous chronic graft versus host disease in treatment with psoralen plus ultraviolet-A-bath photochemotherapy.
    Hoffner MV; Carrizosa Esquivel A; Pulpillo Ruiz A; Herrera Saval A; Conejo-Mir J; Camacho FM
    J Drugs Dermatol; 2009 Nov; 8(11):1027-9. PubMed ID: 19894371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression?
    Marshall SR
    Nat Clin Pract Oncol; 2006 Jun; 3(6):302-14. PubMed ID: 16757968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children.
    Fang B; Song Y; Lin Q; Zhang Y; Cao Y; Zhao RC; Ma Y
    Pediatr Transplant; 2007 Nov; 11(7):814-7. PubMed ID: 17910665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease.
    Auletta JJ; Cooke KR
    Curr Opin Pediatr; 2009 Feb; 21(1):30-8. PubMed ID: 19242239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel application of lentiviral vectors towards treatment of graft-versus-host disease.
    Scaife MD; Neschadim A; Fowler DH; Medin JA
    Expert Opin Biol Ther; 2009 Jun; 9(6):749-61. PubMed ID: 19456209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
    Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
    Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.